• 1.5% eye drops with and with out preservative are also approved -  unlicensed and

• For use in the treatment of acanthamoeba keratitis – used with PHMB.

• 0.1% and 0.3% eye drops.

• 100microgram in 0.1ml (0.1%) - preservative-free eye drops.

• For the treatment of ophthalmic zoster.

• Preservative-free eye drops are also approved.
  
  • 0.1% Minims® - first choice.
  • 0.1% preservative free eye drops unlicensed - approved only for patients who are unable to use Minims®due to dexterity problems.
  
  

First choice

Unit dose vials (Minims®)

Alternative

Eye drops (unlicensed) - only for patients who are unable to use Minims® due to dexterity problems

• Eye drops and eye ointment

• For use in patients who experience ocular hypertension with other corticosteroids – treatment to be initiated with the advice of an ophthalmologist.

• Approved as a second line agent to conventional corticosteroid eye drops, treatment to be imitated with the advice of an ophthalmologist only.

• The following formulations are approved
  
  • 0.5% eye drops and 1% (Pred-Forte).
  • 0.1% and 0.3% eye drops - both unlicensed.
  
  
• Approved preservative free formulations include
  
  • 0.5% minims.
  • 0.1%, 0.3%, 0.5% and 1% - all unlicensed.
  
  

• For use where Fluorometholone (FML) drops (which are much cheaper) are likely to be insufficiently effective.
  
  

• Approved for macular oedema following central retinal vein occlusion
  in line with NICE.
• Approved for treating diabetic macular oedema in line with NICE.
• Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy

Ikervis®

• Approved as a possible treatment for people with dry eye disease that has not improved despite treatment with artificial tears NICE. 

Verkazia®

• Approved for the treatment of severe vernal keratoconjunctivitis in children and adolescents. 
• If treatment is longer than 12 months then 3-6 monthly reviews will be required. 

• A 0.2% eye ointment is also approved as an alternative to eye drops for this indication   and unlicensed.

• A 2% preservative free preparation is also approved unlicensed -  treatment to be imitated with the advice of an ophthalmologist only.

• 40mg Injection
• Approved for the treatment of children with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
• Approved for the treatment of adults with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
• Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy (replaces interim policy for adalimumab for adults with severe refractory uveitis from 24th October 2017)

• 1% eye drop.
  1% ointment.
  1% preservative-free eye drops unlicensed.

• 0.5% and 1%.

• 0.5% and 1%.

• 0.3ml injection containing procaine HCl 6mg, atropine sulphate 1mg and adrenaline solution (1:1,000)

• 2.5% eye drops unlicensed
• 2.5% single use Minims®

• 2.5% eye drops unlicensed.
• 2.5% single use Minims®.

• 0.3ml injection containing procaine HCL 6mg, atropine sulphate 1mg and adrenaline solution (1 in 1,000).

• 0.25% and 0.5% eye drops.
  0.25% and 0.5% unit dose eye drops.

• 0.25% and 0.5% long-acting eye drops.

• For use as a second/third-line agent in patients insufficiently responsive
  to monotherapy with a prostaglandin analogue or beta blocker

• For use as a second/third-line agent in patients insufficiently responsive
  to monotherapy with a prostaglandin analogue or beta blocker.

• Approved for use in children and adults. To be initiated by ophthalmologists only and is to be used third line after preservative containing latanoprost and preservative free timolol. The ophthalmologists must clearly document that signs and symptoms of preservative intolerance/ allergy have been demonstrated in their patient prior to initiation.

• Approved as a third line agent as an “add-on” in patients at the very end of medical management.

250mg tablets 
500mg injection 

• Eye drops and unit dose eye drops
• Approved for use in patients with confirmed allergy presenting as
  conjunctival changes or skin allergy. To be initiated by ophthalmologists
  only. The ophthalmologists must clearly document that signs and
  symptoms of preservative allergy have been demonstrated in their
  patient prior to initiation.

• 0.5%, 1%, 2% and 4% eye drops.
• 1%, 2% and 4% unit dose eye drops.

• Sterile solution containing sodium chloride 0.64%, sodium acetate 0.39%, sodium citrate 0.17%, calcium chloride 0.048%, magnesium chloride 0.03%, potassium chloride 0.075% in 15ml bottles and 500ml bags.
• For intra-ocular or topical irrigation during surgical procedures.

• Viscotears® eye drops
• GelTears® single unit dose eye drops

• 0.5% and 1% eye drops.

• Please note
  The brand name will soon change to Sooth Night-time and Duolube will be unable to be ordered

• 5g eye ointment

• 0.9% eye drops and single dose unit eye drops.
• 5% eye drops and preservative-free eye drops.
• 5% eye ointment unlicensed.

• 0.1% eye drops & preservative-free eye drops
• 0.2% eye drops & preservative-free eye drops
• 0.4% unit dose vials (Clinitas) & 0.4% preservative-free eye drops (Clinitas Multi)   - specialist recommendation for the treatment of Keraconjunctiva sicca, post refractive surgery and Corneal healing disorders.

• 10ml multidose bottles 0.8ml preservative-0free vials Contains hydroxypropyl guar, polyethylene glycol 400, propylene glycol (and other ingredients).
• Long-acting ocular lubricant used for the treatment of dry eye syndrome. Liquid formulation which turns into a gel on contact with eyes providing fast and long lasting relief. The multidose bottle may be used for up to six months after opening in primary care. In contact lens wearers, Systane should be applied before inserting lenses and after removal to extend comfortable wearing times.

• 2% minims eye drops
• 1mg ophthalmic strips
• Fluorets
• 10% 5ml & 20% 5ml injections unlicensed

25mg injection.

• 0.1% eye drops and unit dose eye drops.
• For post-operative inflammation limited to patients where corticosteroids are unsuitable.

• 20mg in 2ml injection.

• 0.5% and 1% ophthalmic solution.

• 2% 2.3ml intraocular injection.

• 0.5% eye drops.

• For use in eye surgery only. 

• 10mg in 1ml bag (Z-Hyalin®, formerly Ophthalin Gelbag®)
• 14mg in 1ml syringe (Healon GV®)

• Injection for use in cataract surgery containing VisCoat (1% sodium hyaluronate) and ProVisc (3% sodium hyaluronate, 4% chondroitin sulphate).

• For use in the debridement of the corneal epithelium in patients with
  recurrent corneal erosion syndrome.

• Approved for wet age related macular degeneration in line with NICE.
• Approved for macular oedema – central retinal vein occlusion in line with NICE.
• Approved for diabetic macular oedema in line with NICE.
• Approved for treating visual impairment caused by macular oedema after branch retinal vein occlusion in line with NICE.
• Approved as an option for treating visual impairment because of myopic choroidal neovascularisation in adults in line with NICE

• Approved for wet age related macular degeneration in line with NICE/.
• Approved for diabetic macular oedema in line with NICE.
• Approved for visual impairment caused by macular oedema secondary
  to retinal vein occlusion in line with NICE.
• Approved as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia in line with NICE.

Approved for photodynamic therapy in wet age-related macular degeneration in line NICE.

• NETAG approved for use in the management of macular oedema
  secondary to retinal vein occlusion. This is considered a more cost
  effective treatment option in RVO compared with ranibizumab.
• NTAG approved for age related macular degeneration.

• Approved for use in patients with vitreomacular traction who also have no epiretinal membrane and a hole (up to 400 micrometres) in the centre of their retina or severe sight problems in line with NICE.

• Approved for treating limbal stem cell deficiency after eye burns in line with NICE and NHS England Commissioning Policy as of 14 November 2017